Islet Holdings, Inc. (ISHI) 株価（米ドル）

In April 2009, through its subsidiary Isletech, Inc., the Company acquired certain intellectual property in the medical field of treating Type 1 diabetes. Thereafter, the Company modified its prior focus on cosmeceuticals and continued its operations, but as a biotech medical company engaged in the research, development, and commercialization of patented technologies in the field of transplantation therapy for people with conditions of insulin-dependent diabetes. Following disagreements in later 2009 and 2010 with certain parties related to the Company's work and development in the Type 1 diabetes treatment industry, the Company was forced to file suit to protect the patents and other intellectual property it acquired in 2009. In August 2012, the Company and its subsidiary filed suit in Federal District Court for the District of Utah. Despite intermittent settlement discussions, the matter remains unresolved and the Company continues to devote its primary resources and efforts to protect its patents and other intellectual property. In the first quarter of 2014 the Company commenced research into developing markets in the cannabis industry. In particular, the Company became interested in the use of cannabinoids in general, and cannabidiol (CBD) in particular, for treatment of a variety of medical ailments. In January 2015, the Company entered into an agreement with Apollon Formularies, Inc. to 1) acquire CBD derived from hemp farming in Jamaica, 2) formulate CBD infused products for the company, and 3) sell CBD infused products in Jamaica. The Company believes that Apollon will successfully obtain a license for hemp production in Jamaica, though at the time of this report that had not yet occurred. The Company also entered into an agreement with Last Call Ventures, Inc., an affiliate of Apollon, to acquire products it has developed and benefit from its industry contacts and associations. During the quarter, the Company issued 49,700,000 shares for the Apollon and Last Call agreement and for consulting in conjunction with expansion into CBD research, development, and production. At October 2005, the Company had provided over $500,000 in funding to Apollon and Last Call. These funds, along with shares issued in connection with these agreements and endeavors, represent a major investment and commitment on the part of the Company to obtain reliable sources of CBD and develop opportunities in nutraceutical products. The Company has also entered into a "Sponsorship Agreement for the Research, Development and Trial Testing of New Agricultural Crops" with SproutHouse LLC in Colorado. The SproutHouse Agreement provides for the acquisition of CBD from Colorado hemp and data for the domestic growing of various strains of hemp and subsequent CBD extraction. The Company plans to aggressively accumulate and organize all data related to the foregoing activities for the purpose of developing valuable intellectual property in the CBD industry.